Clinical Study for Synergistic Effect of Qingzhihuayu Granule and Atorvastatin on sdLDL-C/LDL-C of Patients With Coronary Atherosclerotic Heart Disease

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900025853

Enrollment

Unknown

Registered

2019-09-11

Start date

2019-09-30

Completion date

Unknown

Last updated

2020-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Atherosclerotic Heart Disease

Interventions

atorvastatin + traditional Chinese medicine group:Qingzhihuayu Granule+Atorvastatin

atorvastatin + placebo control group:Placebo+Atorvastatin

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Objectives: Patients with coronary atherosclerotic heart disease (CAD). And whose statin treatment effect is not good, blood lipid did not meet the standard. Diagnostic criteria: The diagnostic criteria refers to 2016 ACC/AHA diagnostic criteria for CAD: coronary angiography results show that any coronary artery stenosis is more than 50%; CAD lipid standards refer to the ATP standard: LDL-C 1.8 mmol/L was defined for patients whose blood lipids did not meet the standard after taking statin at the conventional dose. Selection criteria: 1) Age between 18 and 80 (including 18 and 80); 2) Gender is not limited; 3) Coronary angiography showed that the stenosis of any coronary artery exceeded 50%. 4) sdLDL-C (>= 0.77 mmol/L) 5) Patients willing to receive atorvastatin treatment and Traditional Chinese Medicine treatment.

Exclusion criteria

Exclusion criteria: 1) History of statin-related liver lesions and/or myopathy; 2) Patients with malignant tumors (excluding those cured); 3) Patients with serious diseases of heart, lung, kidney, brain and blood; 4) Patients with severe neurological and psychiatric disorders (such as epilepsy, depression, mania, seizures, schizophrenia, etc.); 5) Pregnant women and lactating women or those who have pregnancy plans and are unwilling to contracept during the study period; 6) Participate in other clinical researchers at the same time; 7) Researchers think that it is not suitable for patients to participate in this study.

Design outcomes

Primary

Measure	Time frame
sdLDL-C;	—

Secondary

Measure	Time frame
LDL-C;sdLDL-C/LDL-C;TC;TG;HDL-C;Cardiovascular events;Life Quality Improvement;	—

Countries

China

Contacts

Public ContactZhou Hua

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

zhouhuam@hotmail.com+86 13061717598

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026